El Aragon Health Research Institute (IIS Aragón), organized with the collaboration of Ibercaja Foundation this "Cycle of keynote lectures» with the aim of promoting the cardiovascular health of the Aragonese.
The cycle consisting of five “keynote lectures” scheduled for the months of June, September, October, November and December, it covers different themes: sleep breathing disorders, dialogue about our habits, nutrition in early childhood, healthy aging, and finally our genes, all of them especially interesting subjects in the care of our cardiovascular health.
PROGRAMME
«Sleep disorders and cardiovascular disease, imparts the Dr. José Mª Marín Trigo, doctor at the Pulmonology Service, Miguel Servet University Hospital. Professor of Pulmonology at the University of Zaragoza.
Sleep occupies a third of human life and during this time the biological functions that allow “quality sleep” are maintained. This exhibition indicates the main sleep disorders and their consequences for general and especially cardiovascular health.
«Tobacco: a bad dream, imparts the Dr. Rodrigo Córdoba García, family doctor and associate professor at the Faculty of Medicine of Zaragoza. Delegate in Aragon of the National Committee for the Prevention of Smoking (CNPT).
"A little cigarette, off to bed." Many people associate this custom with relaxing before going to sleep. But the reality is that, as with alcohol, in the end you sleep worse. Nicotine and alcohol consumption within 4 hours of bedtime is associated with increased sleep fragmentation, poor sleep quality, and risk of obstructive sleep apnea syndrome. Quitting smoking is the first health priority. There are more than enough reasons to do so.
It concludes with a colloquium that mthey oder:
Dr. Miguel A. Guerrero Cásedas. Responsible for the Ibercaja Prevention Service.
Dr. Martín Laclaustra Gimeno. Full Professor of Medicine at the University of Zaragoza. Researcher at the Aragón Health Research Institute (IIS Aragón). Researcher at the Network Biomedical Research Center for Cardiovascular Diseases (CIBERCV).